<!DOCTYPE  html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8"/><title>Index</title><link href="navigation.css" rel="stylesheet" type="text/css"/><link href="document.css" rel="stylesheet" type="text/css"/></head><body><p class="top_nav"><a href="part30.htm">&lt; Назад</a><span> | </span><a href="../index.html">Содержимое</a></p><p style="padding-top: 4pt;padding-left: 48pt;text-indent: 0pt;text-align: left;"><a name="bookmark81"><h2 href="#bookmark22">Index</h2></a><a name="bookmark82">&zwnj;</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Tables and figures are indicated by <i>t </i>and <i>f </i>following the page number.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s138" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">abdominal anatomy 340<i>f </i>abdominal computed tomography</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">acute abdomen 318–19</p><p class="s138" style="padding-left: 5pt;text-indent: 8pt;line-height: 83%;text-align: left;">obstructions 321, 322<i>f </i>abdominoperineal resection (APR) 166 absorbed dose 357–58</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 9pt;text-align: left;">accuracy definition 4</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 9pt;text-align: left;">acute abdomen 318–22</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">acute oesophagitis 75 acute pneumonitis 77, 78<i>f </i>adaptive radiotherapy 2</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">image-guided radiotherapy 43</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">ADC <i>see </i>apparent diffusion coefficient (ADC) adenocarcinoma</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">gastric tumours 108</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">lung cancer 64</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 83%;text-align: left;">oesophageal cancer 101 parotid gland tumours 213</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">adenoid cystic carcinomas 213 adenomas</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">hepatic adenoma 115<i>t</i></p><p class="s138" style="padding-left: 5pt;text-indent: 8pt;line-height: 83%;text-align: left;">pituitary adenoma 245–46, 246<i>f </i>adolescents 362</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 9pt;text-align: left;">adrenal medulla 297</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">adrenocortical tumours 272 air artefacts 352, 353<i>f</i></p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">alveolar rhabdomyosarcoma (aRMS) 310 anal cancer 160</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">anaplastic large T-cell lymphoma 87<i>t </i>anaplastic oligodendroglioma</p><p class="s138" style="padding-left: 5pt;text-indent: 16pt;line-height: 83%;text-align: left;">(grade III) 233, 234<i>f </i>anaplastic thyroid cancer 217<i>t</i></p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">angioimmunoblastic T cell lymphoma 87<i>t </i>apparent diffusion coefficient (ADC) 42–43 As Low As Reasonably Achievable</p><p class="s138" style="padding-left: 21pt;text-indent: 0pt;line-height: 9pt;text-align: left;">(ALARA) 338</p><p class="s139" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">Aspergillus fumigatus <span class="s138">infection 324, 325</span>f <span class="s138">astrocytomas 226–32</span></p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 83%;text-align: left;">anaplastic astrocytomas 228–29, 230<i>f </i>diffuse astrocytoma 229–31, 230<i>f </i>glioblastomas (grade IV) 226–28, 228<i>f </i>pilocytic astrocytomas 231<i>f</i>, 231–32</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">atelectasis, thoracic cancer 350–51 attenuation, ultrasound 12 avascular necrosis (AVN) 329, 330<i>f</i></p><p class="s138" style="padding-top: 9pt;padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">beam filtration, radiography imaging 5 beam’s eye view (BEV) 73, 74<i>f </i>Beckwith–Wiedemann syndrome 294</p><p class="s138" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 10pt;text-align: left;">benign dystrophic calcification 61</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">benign nerve sheath tumours 247–48, 248<i>f </i>β-human chorionic gonadotrophin</p><p class="s138" style="padding-left: 21pt;text-indent: 0pt;line-height: 9pt;text-align: left;">(βHCG) 292</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">biliary tumours 114 biopsies</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">breast cancer 48–49, 49<i>t</i></p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 83%;text-align: left;">computed tomography-guided 66<i>f</i>, 66 gastrointestinal stromal tumours 138 hepatocellular carcinoma 117–18</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 83%;text-align: left;">lung cancer 65, 66<i>f </i>lymphoma 84</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 83%;text-align: left;">paediatric renal tumours 295 primary bone sarcoma 285 soft tissue sarcoma 253 testicular cancer 183</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 9pt;text-align: left;">bladder 348<i>f</i>, 348</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 9pt;text-align: left;">bladder cancer 178–81</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">clinical background 178</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">diagnosis 178</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 83%;text-align: left;">radiotherapy planning 180–81 staging 178–80, 179<i>f</i>, 180<i>f</i></p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">therapeutic assessment/follow-up 181</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">bleomycin-induced pneumonia 327–28 bone metastases</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 83%;text-align: left;">breast cancer 54–56, 55<i>f </i>prostate cancer M staging 172</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">bone mineral density (BMD) 328 bone scans 65</p><p class="s138" style="padding-left: 5pt;text-indent: 8pt;line-height: 83%;text-align: left;">isotope bone scans 22–23, 23<i>f</i>, 54 bone scintigraphy</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 83%;text-align: left;">pelvic insufficiency fractures 328–29 primary bone sarcoma diagnosis/</p><p class="s138" style="padding-left: 21pt;text-indent: 0pt;line-height: 9pt;text-align: left;">staging 276<i>t</i>, 283, 284<i>f</i></p><p class="s138" style="padding-left: 21pt;text-indent: -8pt;line-height: 83%;text-align: left;">primary bone sarcoma treatment response/ follow-up 286</p><p class="s138" style="padding-left: 21pt;text-indent: -8pt;line-height: 83%;text-align: left;">prostate cancer therapeutic assessment/ follow-up 176–77</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 9pt;text-align: left;">bone tumours</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 83%;text-align: left;">chondrogenic bone sarcomas 275 primary bone tumours 309</p><p class="s138" style="padding-left: 5pt;text-indent: 8pt;line-height: 83%;text-align: left;">primary sarcoma <i>see </i>primary bone sarcomas Bosniak classification, renal cysts 188<i>t</i></p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 9pt;text-align: left;">bowel perforation 322</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">brachial plexopathy 62 brachytherapy</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 83%;text-align: left;">cervical cancer radiotherapy planning 201 high dose rate 42–43, 175</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">penile cancer radiotherapy planning 186–87</p><p class="s138" style="padding-top: 5pt;padding-left: 13pt;text-indent: 0pt;line-height: 10pt;text-align: left;">brachytherapy (<i>cont.</i>)</p><p class="s138" style="padding-left: 27pt;text-indent: -8pt;line-height: 83%;text-align: left;">prostate cancer radiotherapy planning 175, 176<i>f</i>, 177<i>f</i></p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">vaginal cancer 203</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">brain, radiotherapy planning 38 brain metastases 242–43</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">breast cancer 56</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">lung cancer 70</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 9pt;text-align: left;">brainstem 38</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 9pt;text-align: left;">breast cancer 46</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">brain metastases 56</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 83%;text-align: left;">HER2-positive breast cancer 54 imaging radiation dose 367<i>t</i>, 369 incidence 46–47</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">liver metastases 56</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">metastases 54, 62</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">pleural effusions 56</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">radiological diagnosis 47–53</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">radiological staging 53–56</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">radiotherapy planning 40, 56–60</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">screening 46</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">triple negative breast cancer 54</p><p class="s139" style="padding-left: 11pt;text-indent: 8pt;line-height: 83%;text-align: left;">see also <span class="s138">ductal carcinoma </span>in situ <span class="s138">(DCIS) breast conservation surgery (BCS) 56 breast lymphoedema 61</span>f<span class="s138">, 61</span></p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">breathing motion, artefacts 354 bronchoscopy 65</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">BTV (biological target volume) 38 Burkitt lymphoma 87<i>t</i></p><p class="s138" style="padding-top: 7pt;padding-left: 11pt;text-indent: 0pt;line-height: 10pt;text-align: left;">calcification 48–49, 61</p><p class="s139" style="padding-left: 11pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Candida <span class="s138">infections 324</span></p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 9pt;text-align: left;">carboplatin 185</p><p class="s138" style="padding-left: 19pt;text-indent: -8pt;line-height: 83%;text-align: left;">carcinoembryonic antigen (CEA) 133, 135 rectal cancer surveillance 158</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">central nervous system (CNS) 38–39, 39<i>f </i>central nervous system (CNS)</p><p class="s138" style="padding-left: 27pt;text-indent: 0pt;line-height: 9pt;text-align: left;">tumours 222</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 83%;text-align: left;">astrocytomas <i>see </i>astrocytomas benign nerve sheath tumours 247–48,</p><p class="s138" style="padding-left: 27pt;text-indent: 0pt;line-height: 9pt;text-align: left;">248<i>f</i></p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">brain metastases 242–43</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">craniopharyngiomas 246–47, 247<i>f</i></p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">embryonal tumours 238–39</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">ependymoma 236, 237<i>f</i></p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">intra-parenchymal tumours 226</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">intraparenchymal imaging 225</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">medulloblastoma 238–39, 239<i>f</i></p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">meningioma 244<i>f</i>, 244–45</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 83%;text-align: left;">mixed gliomas <i>see </i>mixed gliomas oligodendrogliomas <i>see </i>oligodendromas pineal lesions <i>see </i>pineal lesions</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 83%;text-align: left;">pituitary adenoma 245–46, 246<i>f </i>primary CNS lymphoma 239–40, 240<i>f </i>sellar region 245–47</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 83%;text-align: left;">soft tissue sarcoma metastases 256, 257<i>f </i>spinal cord myxopapillary ependymoma</p><p class="s138" style="padding-left: 11pt;text-indent: 16pt;line-height: 83%;text-align: left;">(grade II) 237–38 cerebrospinal fluid (CSF) 85 cervical cancer 198–202</p><p class="s138" style="padding-top: 6pt;padding-left: 19pt;text-indent: 0pt;line-height: 83%;text-align: left;">clinical background 198 diagnosis/staging 198–200, 199<i>t</i>, 200<i>f </i>radiotherapy planning 200–1</p><p class="s138" style="padding-left: 11pt;text-indent: 8pt;line-height: 83%;text-align: left;">therapeutic assessment/follow-up 201–2, 202<i>f </i>cervical lymphadenectomy 84<i>f </i>chemoradiotherapy (CRT)</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">gastric cancer 111</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">oesophageal cancer 103</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">pancreatic tumours 134</p><p class="s138" style="padding-left: 11pt;text-indent: 8pt;line-height: 83%;text-align: left;">rectal cancer 148 chemotherapy</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 83%;text-align: left;">induced lung injury 327–28 lung cancer 74–75</p><p class="s138" style="padding-left: 11pt;text-indent: 8pt;line-height: 83%;text-align: left;">thoracic cancer 350–51 chest radiography</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">lung cancer 65</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">lymphangitis carcinomatosis 326</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">lymphoma 83–84, 84<i>f</i></p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 83%;text-align: left;">paediatric lymphoma 302–3 paediatric renal tumour diagnosis/</p><p class="s138" style="padding-left: 27pt;text-indent: 0pt;line-height: 9pt;text-align: left;">staging 295</p><p class="s138" style="padding-left: 27pt;text-indent: -8pt;line-height: 83%;text-align: left;">paediatric renal tumours therapeutic assessment/follow-up 296</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 83%;text-align: left;">pleural effusions in breast cancer 56 pulmonary embolism 317</p><p class="s138" style="padding-left: 11pt;text-indent: 8pt;line-height: 83%;text-align: left;">radiation-induced lung injury 326 cholangiocarcinoma (CCA) 118–21</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">background &amp; anatomy 118–19</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">distal cholangiocarcinoma 118, 120–21</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">intrahepatic cholangiocarcinoma 116–17,</p><p class="s138" style="padding-left: 27pt;text-indent: 0pt;line-height: 9pt;text-align: left;">118, 119</p><p class="s138" style="padding-left: 27pt;text-indent: -8pt;line-height: 83%;text-align: left;">mixed hepatocellular cholangiocarcinoma 122</p><p class="s138" style="padding-left: 27pt;text-indent: -8pt;line-height: 83%;text-align: left;">perihilar cholangiocarcinoma <i>see </i>perihilar cholangiocarcinoma (pCCA)</p><p class="s138" style="padding-left: 51pt;text-indent: 0pt;line-height: 9pt;text-align: center;">staging 121</p><p class="s138" style="padding-left: 53pt;text-indent: 0pt;line-height: 9pt;text-align: center;">cholelithiasis 121</p><p class="s140" style="padding-left: 11pt;text-indent: 0pt;line-height: 9pt;text-align: left;">11<span class="s141">C-choline 172</span></p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">chondrogenic bone sarcomas 275 chondrosarcoma 275–76</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">diagnosis/staging 277, 278<i>f</i></p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 9pt;text-align: left;">chordomas 276</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 83%;text-align: left;">inoperable sacral chordomas 285<i>f</i>, 286 sacral chordomas 285<i>f</i>, 286</p><p class="s139" style="padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">Clostridium difficile <span class="s138">infection 319–20 colitis 319–21</span></p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">immune-related 330</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">ischaemic colitis 321</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 9pt;text-align: left;">colorectal cancer 148</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 9pt;text-align: left;">colour Doppler 14</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 9pt;text-align: left;">compression ultrasonography 317–18</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Compton scattering 6</p><p class="s138" style="padding-left: 27pt;text-indent: -16pt;line-height: 83%;text-align: left;">computed tomographic angiography (CTA) 261–62, 262<i>f</i></p><p class="s138" style="padding-left: 27pt;text-indent: -16pt;line-height: 83%;text-align: left;">computed tomographic pulmonary angiography (CTPA) 316, 317<i>f</i></p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 78%;text-align: left;">computed tomographic urography (CTU) 178 computed tomography dose index (CTDI<span class="s142">vol</span>) 361 computed tomography number (Hounsfield</p><p class="s138" style="padding-left: 27pt;text-indent: 0pt;line-height: 9pt;text-align: left;">units) 7, 143–45</p><p class="s138" style="padding-top: 7pt;padding-left: 21pt;text-indent: -16pt;line-height: 83%;text-align: left;">computed tomography–magnetic resonance imaging co-registration 33, 35</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">continuous wave (CW) Doppler 14 contrast agents</p><p class="s138" style="padding-left: 21pt;text-indent: -8pt;line-height: 83%;text-align: left;">contrast-enhanced spectral mammography 49–50, 54</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 83%;text-align: left;">intravenous para-magnetic contrast agents 254 ultrasound 14, 15<i>f</i>, 116–17</p><p class="s138" style="padding-left: 21pt;text-indent: -16pt;line-height: 83%;text-align: left;">contrast artefacts, MRI in radiotherapy planning 33–34</p><p class="s138" style="padding-left: 21pt;text-indent: -16pt;line-height: 83%;text-align: left;">contrast-enhanced spectral mammography (CESM) 49–50, 54</p><p class="s138" style="padding-left: 21pt;text-indent: -16pt;line-height: 83%;text-align: left;">contrast enhanced ultrasonography 14, 15<i>f</i>, 116–17</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">convolution kernels, CT 7 craniopharyngiomas 246–47, 247<i>f</i></p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">CRM (circumferential resection margin) 150 cryptogenic organizing pneumonia (COP) 332 CW (continuous wave) Doppler 14</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">cystoscopy 178, 180–81 cysts</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 83%;text-align: left;">breast cancer 47–48 hepatobiliary tumours 115<i>t </i>renal cysts 188<i>t</i></p><p class="s138" style="padding-top: 9pt;padding-left: 21pt;text-indent: -16pt;line-height: 83%;text-align: left;">DCE-MRI <i>see </i>dynamic contrast enhanced magnetic resonance imaging (DCE-MRI)</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">DCIS (ductal carcinoma <i>in situ</i>) 47 Deauville five point scale 91–92</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">deep venous thrombosis (DVT) 317–18 Denys–Drash syndrome 294</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">detective quantum efficiency 6 deterministic effects of radiation 356 Deuville five point scale 92<i>t</i></p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 9pt;text-align: left;">DFS (Doppler frequency shift) 14</p><p class="s138" style="padding-left: 21pt;text-indent: -16pt;line-height: 83%;text-align: left;">diffuse astrocytoma (grade II non-codeleted glioma) 229–31, 230<i>f</i></p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">diffuse intrinsic pontine gliomas 292<i>f</i>, 292 diffuse large B cell lymphoma 87, 87<i>t </i>diffusion-tension imaging (DTI) 223<i>f</i>, 223,</p><p class="s138" style="padding-left: 21pt;text-indent: 0pt;line-height: 9pt;text-align: left;">228<i>f</i>, 230<i>f</i></p><p class="s138" style="padding-left: 13pt;text-indent: -8pt;line-height: 83%;text-align: left;">diffusion-weighted imaging (DWI) cervical cancer 200</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">CNS tumours 223</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">prostate cancer 168</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">uterine cancer 195</p><p class="s138" style="padding-left: 21pt;text-indent: -16pt;line-height: 83%;text-align: left;">digitally reconstructed radiographs (DRRs) 164–65, 165<i>f</i></p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">DIL (dominant intraprostatic lesion) 174–75, 175<i>f </i>distal cholangiocarcinoma (dCCA) 118, 120–21 DMSA (dimercaptosuccinic acid) 111 dominant intraprostatic lesion (DIL) 174–75, 175<i>f </i>Doppler frequency shift (DFS) 14</p><p class="s138" style="padding-left: 13pt;text-indent: -8pt;line-height: 83%;text-align: left;">Doppler ultrasound 14 gastrointestinal stromal tumour</p><p class="s138" style="padding-left: 21pt;text-indent: 0pt;line-height: 9pt;text-align: left;">diagnosis 142–43</p><p class="s138" style="padding-left: 5pt;text-indent: 8pt;line-height: 83%;text-align: left;">soft tissue sarcoma diagnosis/staging 252, 252<i>t </i>dose area product (DAP) 361</p><p class="s138" style="padding-left: 13pt;text-indent: -8pt;line-height: 83%;text-align: left;">dose length product (DLP) 361 CT 10, 11</p><p class="s138" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">dose volume histograms (DVHs) 74, 111–12 double duct sign 129–30</p><p class="s138" style="padding-left: 21pt;text-indent: -16pt;line-height: 83%;text-align: left;">DRRs (digitally reconstructed radiographs) 164–65, 165<i>f</i></p><p class="s138" style="padding-left: 21pt;text-indent: -16pt;line-height: 83%;text-align: left;">DTI (diffusion-tension imaging) 223<i>f</i>, 223, 228<i>f</i>, 230<i>f</i></p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">ductal carcinoma <i>in situ </i>(DCIS) 47 Dukes’ classification 150, 152<i>t</i></p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">DVT (deep venous thrombosis) 317–18 DWI <i>see </i>diffusion-weighted imaging (DWI)</p><p class="s138" style="padding-left: 21pt;text-indent: -16pt;line-height: 83%;text-align: left;">dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) 19<i>f</i>, 19</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 83%;text-align: left;">breast cancer diagnosis 51 breast cancer staging 53–54 paediatric osteosarcoma 310</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">prostate cancer 168</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">dynamic data acquisition, SPECT 21–22 dynamic range, radiography 6</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">dynamic ultrasound 252 dysthyroid ere disease/thyroid</p><p class="s138" style="padding-left: 21pt;text-indent: 0pt;line-height: 9pt;text-align: left;">orbitopathy 248–49, 249<i>f</i></p><p class="s138" style="padding-top: 8pt;padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">early gastric cancer (EGCs) 109 EBUS (endobranchial ultrasound) 66 echo-planar imaging, MRI 19 echocardiography</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">pulmonary embolism 317</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">transoesophageal 317, 324</p><p class="s138" style="padding-left: 5pt;text-indent: 8pt;line-height: 83%;text-align: left;">transthoracic echocardiography 317 electron density estimation 35 electronic focusing, ultrasound 13</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">electronic portal imaging device (EPID) 365 embryonal rhabdomyosarcoma 310 endobranchial ultrasound (EBUS) 66 endocrine tumours 265</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">adrenocortical tumours 272</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">neuroendocrine neoplasms 265–69</p><p class="s139" style="padding-left: 21pt;text-indent: -8pt;line-height: 83%;text-align: left;">see also <span class="s138">pancreatic neuroendocrine tumours (PNETs); phaeochromocytoma and paraganglioma (PPGLs)</span></p><p class="s138" style="padding-left: 21pt;text-indent: -16pt;line-height: 83%;text-align: left;">endoscopic retrograde cholangiopancreatography (ERCP) 130</p><p class="s138" style="padding-left: 13pt;text-indent: -8pt;line-height: 83%;text-align: left;">endoscopic ultrasound (EUS) gastric tumour diagnosis 108</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 83%;text-align: left;">gastrointestinal stromal tumour 142–43 mucinous neoplasms of pancreas 133 oesophageal cancer staging 99, 101<i>f </i>oesophageal cancer treatment response 105 pancreatic neuroendocrine tumours 266–67 pancreatic tumours 129–30</p><p class="s138" style="padding-left: 5pt;text-indent: 8pt;line-height: 83%;text-align: left;">transoesophageal 66<i>f</i>, 66, 100–1, 189 endoscopic ultrasound fine needle aspiration</p><p class="s138" style="padding-left: 21pt;text-indent: 0pt;line-height: 9pt;text-align: left;">(EUS-FNA)</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">cholangiocarcinoma 121</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 83%;text-align: left;">mucinous neoplasms of pancreas 133 oesophageal cancer staging 99, 102</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 9pt;text-align: left;">endoscopy</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">gastric tumours 108</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 83%;text-align: left;">lower gastrointestinal endoscopy 149 rectal cancer 158</p><p class="s138" style="padding-top: 7pt;padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">endovaginal magnetic resonance imaging 198 ependymoma 236, 237<i>f</i></p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">EPID (electronic portal imaging device) 365 equivalent dose 357–58</p><p class="s138" style="padding-left: 27pt;text-indent: -16pt;line-height: 83%;text-align: left;">ERCP (endoscopic retrograde cholangiopancreatography) 130</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">erythrocyte sedimentation rate (ESR) 84 ESD (entrance skin dose) 361</p><p class="s138" style="padding-left: 27pt;text-indent: -16pt;line-height: 83%;text-align: left;">EUS-FNA <i>see </i>endoscopic ultrasound fine needle aspiration (EUS-FNA)</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Ewing’s sarcoma 275</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">diagnosis/staging 277, 280</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">extended field of view imaging, ultrasound 14 extra-axial CNS tumours 243<i>f</i>, 244–45</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">extra-axial imaging, CNS tumours 225 extramural venous invasion</p><p class="s138" style="padding-left: 27pt;text-indent: 0pt;line-height: 9pt;text-align: left;">(EMVI) 150, 152<i>f</i></p><p class="s138" style="padding-top: 8pt;padding-left: 27pt;text-indent: -16pt;line-height: 83%;text-align: left;">fan beam megavoltage computed tomography (FBMVCT) 339, 346</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 9pt;text-align: left;">FET <span class="s143">(18</span>fluoroethyl-L-tyrosine) 224</p><p class="s140" style="padding-left: 11pt;text-indent: 0pt;line-height: 9pt;text-align: left;">18<span class="s141">F-FMISO positron emission tomography 40, 42</span></p><p class="s140" style="padding-left: 11pt;text-indent: 0pt;line-height: 9pt;text-align: left;">18<span class="s141">F-FAZA 42</span></p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 9pt;text-align: left;">fibreoptic colonoscopy 149</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 9pt;text-align: left;">fibroadenoma 47–48</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 9pt;text-align: left;">fibrosis 326–27, 327<i>f</i></p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">FID (free induction decay) 16 field of view (FOV) 338<i>f</i>, 338 filtered back projection, CT 7 filters, image processing 341–42 FLAIR imaging</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">anaplastic astrocytoma 229</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">CNS tumours 225</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">diffuse astrocytoma 231</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">glioblastoma 227–28</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">mixed glioma 235</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 9pt;text-align: left;">FLT (<span class="s143">18</span>fluorothymidine) 224</p><p class="s140" style="padding-left: 11pt;text-indent: 0pt;line-height: 9pt;text-align: left;">18<span class="s141">F-choline 172</span></p><p class="s140" style="padding-left: 11pt;text-indent: 0pt;line-height: 9pt;text-align: left;">18<span class="s141">fluoroethyl-L-tyrosine (FET) 224</span></p><p class="s140" style="padding-left: 11pt;text-indent: 0pt;line-height: 9pt;text-align: left;">18<span class="s141">fluorothymidine (FLT) 224</span></p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 9pt;text-align: left;">5-fluorouracil (5FU) 111</p><p class="s138" style="padding-left: 27pt;text-indent: -16pt;line-height: 83%;text-align: left;">fMRI (functional magnetic resonance imaging) 169, 226</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">focal nodular hyperplasia 115<i>t </i>follicular lymphoma 87<i>t </i>follicular thyroid cancer 214 4D computed tomography</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">lung cancer 71, 72</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">lymphoma 90</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">oesophageal cancer 104</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">planning systems 2–3</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">4D cone-beam computed tomography 76 4D magnetic resonance imaging 34</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">4D PET/computed tomography 37 Fourier transform 16</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">free induction decay (FID) 16 frequency, ultrasound 13 frequency encoding, MRI 16</p><p class="s138" style="padding-left: 27pt;text-indent: -16pt;line-height: 83%;text-align: left;">functional magnetic resonance imaging (fMRI) 169, 226</p><p class="s138" style="padding-top: 7pt;padding-left: 26pt;text-indent: -16pt;line-height: 83%;text-align: left;">gadolinium-DTPA contrast magnetic resonance imaging 51, 286</p><p class="s138" style="padding-left: 10pt;text-indent: 0pt;line-height: 83%;text-align: left;">gadolinium oxyorthosilicate (GSO) 25 gallbladder carcinoma 121–22, 122<i>f </i>gastric outlet obstruction 321</p><p class="s138" style="padding-left: 10pt;text-indent: 0pt;line-height: 9pt;text-align: left;">gastric tumours 108</p><p class="s138" style="padding-left: 18pt;text-indent: 0pt;line-height: 9pt;text-align: left;">clinical background 108</p><p class="s138" style="padding-left: 18pt;text-indent: 0pt;line-height: 9pt;text-align: left;">diagnosis 108</p><p class="s138" style="padding-left: 18pt;text-indent: 0pt;line-height: 83%;text-align: left;">staging 108–11, 109<i>f</i>, 110<i>f </i>treatment 111–12</p><p class="s138" style="padding-left: 18pt;text-indent: 0pt;line-height: 83%;text-align: left;">treatment assessment and follow-up 112 treatment planning 111–12</p><p class="s138" style="padding-left: 10pt;text-indent: 0pt;line-height: 9pt;text-align: left;">gastrinomas 266</p><p class="s138" style="padding-left: 26pt;text-indent: -16pt;line-height: 83%;text-align: left;">gastroenteropancreatic neuroendocrine tumours (GEP-NETs) 266, 267–68</p><p class="s138" style="padding-left: 18pt;text-indent: -8pt;line-height: 83%;text-align: left;">gastrointestinal stromal tumours (GISTs) 137 clinical presentation 137–38</p><p class="s138" style="padding-left: 18pt;text-indent: 0pt;line-height: 9pt;text-align: left;">diagnosis 137–38</p><p class="s138" style="padding-left: 18pt;text-indent: 0pt;line-height: 9pt;text-align: left;">pathology 138<i>f</i>, 138–39</p><p class="s138" style="padding-left: 18pt;text-indent: 0pt;line-height: 9pt;text-align: left;">prognosis 139, 139<i>t</i></p><p class="s138" style="padding-left: 18pt;text-indent: 0pt;line-height: 83%;text-align: left;">response evaluation 142<i>f</i>, 143–45, 144<i>f </i>surveillance 143–145, 145<i>f</i></p><p class="s138" style="padding-left: 18pt;text-indent: 0pt;line-height: 9pt;text-align: left;">treatment 139–40</p><p class="s138" style="padding-left: 10pt;text-indent: 0pt;line-height: 9pt;text-align: left;">GCTs (giant cell tumours) 276</p><p class="s138" style="padding-left: 26pt;text-indent: -16pt;line-height: 83%;text-align: left;">genitourinary system, soft tissue sarcomas 310, 311<i>f</i></p><p class="s138" style="padding-left: 26pt;text-indent: -16pt;line-height: 83%;text-align: left;">GEP-NET (gastroenteropancreatic neuroendocrine tumours) 266,</p><p class="s138" style="padding-left: 51pt;text-indent: 0pt;line-height: 9pt;text-align: center;">267–68</p><p class="s138" style="padding-left: 54pt;text-indent: 0pt;line-height: 9pt;text-align: center;">germ cell tumours</p><p class="s138" style="padding-left: 18pt;text-indent: -3pt;line-height: 83%;text-align: center;">pineal lesions 241, 242<i>f </i>testicular cancer 182–83</p><p class="s138" style="padding-left: 10pt;text-indent: 0pt;line-height: 83%;text-align: left;">GFR (glomerular filtration rate) 111 giant cell tumours (GCTs) 276</p><p class="s138" style="padding-left: 26pt;text-indent: -16pt;line-height: 83%;text-align: left;">GISTs <i>see </i>gastrointestinal stromal tumours (GISTs)</p><p class="s138" style="padding-left: 10pt;text-indent: 0pt;line-height: 83%;text-align: left;">glioblastomas (grade IV) 226–28, 228<i>f </i>gliomas</p><p class="s138" style="padding-left: 18pt;text-indent: 0pt;line-height: 83%;text-align: left;">diffuse intrinsic pontine 292<i>f</i>, 292 spinal cord gliomas 234–36, 235<i>f</i></p><p class="s138" style="padding-left: 10pt;text-indent: 0pt;line-height: 9pt;text-align: left;">gliomatosis cerebri 234</p><p class="s138" style="padding-left: 10pt;text-indent: 0pt;line-height: 83%;text-align: left;">glomerular filtration rate (GFR) 111 glucagonomas 266</p><p class="s138" style="padding-left: 26pt;text-indent: -16pt;line-height: 83%;text-align: left;">grade III non-correlated glioma (anaplastic astrocytomas) 228–29, 230<i>f</i></p><p class="s138" style="padding-left: 10pt;text-indent: 0pt;line-height: 83%;text-align: left;">gradient echo, MRI 16, 17<i>f </i>gynaecological cancers 193</p><p class="s138" style="padding-left: 18pt;text-indent: 0pt;line-height: 83%;text-align: left;">cervical cancer <i>see </i>cervical cancer ovarian cancer 193</p><p class="s138" style="padding-left: 18pt;text-indent: 0pt;line-height: 83%;text-align: left;">radiotherapy planning 41 uterine cancer <i>see </i>uterine cancer vaginal cancer 202–4</p><p class="s138" style="padding-left: 18pt;text-indent: 0pt;line-height: 10pt;text-align: left;">vulval cancer 204–6</p><p class="s138" style="padding-top: 8pt;padding-left: 10pt;text-indent: 0pt;line-height: 83%;text-align: left;">haemangioma, hepatobiliary tumours 115<i>t </i>haematogenous spread, testicular cancer 183 HDR (high dose rate) brachytherapy 42–43, 175 head and neck</p><p class="s138" style="padding-left: 18pt;text-indent: 0pt;line-height: 9pt;text-align: left;">anatomy 339<i>f</i></p><p class="s138" style="padding-left: 18pt;text-indent: 0pt;line-height: 10pt;text-align: left;">clinical practice 351<i>f</i>, 351–52</p><p class="s138" style="padding-top: 7pt;padding-left: 13pt;text-indent: -8pt;line-height: 83%;text-align: left;">head and neck cancers 208 clinical background 208</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 83%;text-align: left;">dose escalation/dose painting 42 MRI 28–29</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">neck metastases 210</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 83%;text-align: left;">radiotherapy planning 39, 210–11 salivary gland tumours 212–13 surveillance 212</p><p class="s138" style="padding-left: 5pt;text-indent: 8pt;line-height: 83%;text-align: left;">therapeutic assessment/follow-up 211–12, 219–20 head and neck squamous cell carcinoma</p><p class="s138" style="padding-left: 21pt;text-indent: 0pt;line-height: 9pt;text-align: left;">(HNSCC) 208–12</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">diagnosis 208–9</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">primary site 209–10</p><p class="s138" style="padding-left: 5pt;text-indent: 8pt;line-height: 83%;text-align: left;">staging 209–10 hepatic abscesses 115<i>t </i>hepatic cancer 114</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">hepatic adenoma 115<i>t</i></p><p class="s139" style="padding-left: 21pt;text-indent: -8pt;line-height: 83%;text-align: left;">see also <span class="s138">hepatobiliary tumours; hepatocellular carcinoma (HCC)</span></p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 9pt;text-align: left;">hepatitis, immune-related 331</p><p class="s138" style="padding-left: 13pt;text-indent: -8pt;line-height: 83%;text-align: left;">hepatobiliary tumours 114 anatomy 120<i>f</i></p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 83%;text-align: left;">differential diagnosis 114, 115<i>t</i>, 116<i>t </i>metastases imaging 116<i>t </i>radiotherapy 125</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">systemic therapies 125–26</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">therapeutic assessment/follow-up 122–26</p><p class="s139" style="padding-left: 21pt;text-indent: -8pt;line-height: 83%;text-align: left;">see also <span class="s138">cholangiocarcinoma (CCA); gallbladder carcinoma</span></p><p class="s138" style="padding-left: 13pt;text-indent: -8pt;line-height: 83%;text-align: left;">hepatocellular carcinoma (HCC) 114–18 background &amp; anatomy 114–15 diagnosis 27, 117<i>f</i></p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">incidence 114–15</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">non-invasive diagnosis 115–16</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">staging 118, 119<i>t</i></p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">hepatoduodenal nodes 110 HER2-positive breast cancer 54 hippocampus 38</p><p class="s138" style="padding-left: 13pt;text-indent: -8pt;line-height: 83%;text-align: left;">Hodgkin lymphoma (HL) children 302</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">definition 82</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">diagnosis 87</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">spread of 83–84</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 83%;text-align: left;">therapeutic response 93–95 thoracic radiography 84<i>f</i></p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Honda sign 328–29</p><p class="s138" style="padding-left: 21pt;text-indent: -16pt;line-height: 83%;text-align: left;">Hounsfield units (computed tomography number) 7, 143–45</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">HPV (human papilloma virus) infection 160, 208 hybrid imaging 44</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">hydrophilic localization clips 52 hyperlucency 327</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">hypophysitis, immune-related 332, 333<i>f </i>hysterectomy, radical 200</p><p class="s138" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;line-height: 10pt;text-align: left;">ilium 328–29</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 9pt;text-align: left;">image-guided radiotherapy (IGRT) 2, 29–30,</p><p class="s138" style="padding-left: 21pt;text-indent: 0pt;line-height: 9pt;text-align: left;">43, 335, 339–46</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">bladder cancer 180–81</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 10pt;text-align: left;">breast cancer 60</p><p class="s138" style="padding-top: 7pt;padding-left: 13pt;text-indent: 0pt;line-height: 83%;text-align: left;">image processing for 3D image review 341–42 imaging and 342, 363</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">PET 27</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">planning 32</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">rectal cancer 156</p><p class="s138" style="padding-left: 21pt;text-indent: -8pt;line-height: 83%;text-align: left;">volumetric match techniques 342–46, 343–45<i>t</i>, 346<i>f</i></p><p class="s138" style="padding-left: 13pt;text-indent: -8pt;line-height: 83%;text-align: left;">image processing CT 9–10</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">3D image review 341<i>f</i>, 341–42</p><p class="s138" style="padding-left: 13pt;text-indent: -8pt;line-height: 83%;text-align: left;">immune-related adverse events (irAE) 329–32 immune-related colitis 330</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">immune-related hepatitis 331</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 83%;text-align: left;">immune-related hypophysitis 332, 333<i>f </i>immune-related pneumonitis 331–32, 332<i>f</i></p><p class="s139" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">in vivo <span class="s138">dosimetry artefacts 352 infraclavicular fossa (ICF) 56 inoperable sacral chordomas 285</span>f<span class="s138">, 286</span></p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">INRT (involved-node radiotherapy) 89–91 internal mammary nodal chain (IMC) 50 internal target volume (ITV) 72</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">interstitial pneumonia 332 intra-axial CNS tumours 225</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">intra-parenchymal tumours 226 intraductal papillary mucinous neoplasms</p><p class="s138" style="padding-left: 21pt;text-indent: 0pt;line-height: 9pt;text-align: left;">(IPMNs) 132, 133</p><p class="s138" style="padding-left: 21pt;text-indent: -16pt;line-height: 83%;text-align: left;">intrahepatic cholangiocarcinoma (iCCA) 116–17, 118, 119</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">intramammary node, breast cancer 47–48 intraparenchymal imaging, CNS tumours 225 intravenous para-magnetic contrast agents 254 involved-node radiotherapy (INRT) 89–91 <span class="s143">123</span>iodine 20</p><p class="s140" style="padding-left: 5pt;text-indent: 0pt;line-height: 9pt;text-align: left;">131<span class="s141">iodine 20</span></p><p class="s138" style="padding-left: 21pt;text-indent: -16pt;line-height: 83%;text-align: left;">ionising radiation (medical exposure) regulations (IR(ME)R 2017) 338, 359–60</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 83%;text-align: left;">diagnostic reference levels 361 duty holders 359</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">employers 359</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">incident reporting 362</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 83%;text-align: left;">infants/children/young adults 362 medical physics expert 360 operators 360</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">practitioners 360</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">pregnancy status 361–62</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">quality assurance 362–63</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">referrers 360</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">risk assessment 364</p><p class="s139" style="padding-left: 5pt;text-indent: 8pt;line-height: 83%;text-align: left;">see also <span class="s138">radiation protection issues IPMNs (intraductal papillary mucinous</span></p><p class="s138" style="padding-left: 21pt;text-indent: 0pt;line-height: 9pt;text-align: left;">neoplasms) 132, 133</p><p class="s138" style="padding-left: 21pt;text-indent: -16pt;line-height: 83%;text-align: left;">IR(ME)R <i>see </i>ionising radiation (medical exposure) regulations (IR(ME)R 2017)</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 9pt;text-align: left;">ischaemic colitis 321</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 10pt;text-align: left;">isotope bone scans 22–23, 23<i>f</i>, 54</p><p class="s138" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;line-height: 10pt;text-align: left;">kilovoltage</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 83%;text-align: left;">cone beam computed tomography 365 CT 8</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">imaging 365</p><p class="s138" style="padding-top: 7pt;padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">large cell tumours, lung cancer 64 Larmor equation 15</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Larmor frequency 15</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 9pt;text-align: left;">laryngeal cartilage 210</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">left ventricular luminal volume 23 leiomyomas 195–96</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 9pt;text-align: left;">leiomyosarcomas 195–96</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">uterine cancer 255</p><p class="s138" style="padding-left: 27pt;text-indent: -16pt;line-height: 83%;text-align: left;">LI-RADS (Liver Imaging-Reporting and Data System) 115–16</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">linear non-threshold (LNT) model 356–57 lipomatous lesions 253</p><p class="s138" style="padding-left: 27pt;text-indent: -16pt;line-height: 83%;text-align: left;">Liver Imaging-Reporting and Data System (LI-RADS) 115–16</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">liver metastases, breast cancer 56 LSO (lutetium oxyorthosis) 25 lung cancer 64–77</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">clinical background 64–65</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">comorbidities 65</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">diagnosis 65–67</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 83%;text-align: left;">dose escalation/dose painting 42 histology 64</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">radiotherapy planning 39–40, 70–76</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">screening parameters 64</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 83%;text-align: left;">small-cell <i>see </i>small-cell lung cancer (SCLC) staging 67–70</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 83%;text-align: left;">therapeutic assessment/follow-up 76–77 treatment verification 76, 77<i>f</i>, 78<i>f</i></p><p class="s139" style="padding-left: 27pt;text-indent: -8pt;line-height: 83%;text-align: justify;">see also <span class="s138">non-small cell lung cancer (NSCLC); pulmonary embolism (PE); small-cell lung cancer (SCLC)</span></p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 9pt;text-align: left;">lungs</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 83%;text-align: left;">post-breast cancer therapy 61 radiation-induced lung injury 326–27</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">lutetium oxyorthosis (LSO) 25 lymph nodes</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">anatomy 82, 83<i>f</i></p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 83%;text-align: left;">enlargement in lymphoma 82 papillary carcinoma lymph nodes 218 rectal cancer staging 153–54</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">renal cell carcinoma staging 189</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 83%;text-align: left;">soft tissue sarcoma metastases 255–56 specific contrast agents 172</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">lymphangitis carcinomatosis 324–26, 326<i>f </i>lymphatic spread, penile cancer staging 186 lymphoma 82</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 83%;text-align: left;">anaplastic large T-cell lymphoma 87<i>t </i>anatomical imaging 85–89 angioimmunoblastic T cell lymphoma 87<i>t </i>Burkitt lymphoma 87<i>t</i></p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">definition 82</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">diagnosis 83–85</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 83%;text-align: left;">diffuse large B cell lymphoma 87, 87<i>t </i>FDG-PET 30</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 83%;text-align: left;">follicular lymphoma 87<i>t </i>imaging radiation dose 368<i>t</i>, 369 mantle cell lymphoma 87<i>t</i></p><p class="s138" style="padding-left: 27pt;text-indent: -8pt;line-height: 83%;text-align: left;">mucosa-associated lymphoid tissue lymphoma 87<i>t</i></p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">natural killer cell lymphoma 87<i>t</i></p><p class="s138" style="padding-top: 7pt;padding-left: 27pt;text-indent: -8pt;line-height: 83%;text-align: left;">non-Hodgkin lymphoma <i>see </i>non-Hodgkin lymphoma (NHL)</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 83%;text-align: left;">orbital lymphoma 249 peripheral T cell lymphoma 87<i>t</i></p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 83%;text-align: left;">primary CNS lymphoma 239–40, 240<i>f </i>radiotherapy planning 41, 89–91, 90<i>f </i>small lymphocytic lymphoma 87<i>t </i>staging 89</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">T cell lymphoma 87<i>t</i></p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">therapeutic response/follow up 91–96</p><p class="s139" style="padding-left: 27pt;text-indent: -8pt;line-height: 83%;text-align: left;">see also <span class="s138">Hodgkin lymphoma (HL); non-Hodgkin lymphoma (NHL)</span></p><p class="s138" style="padding-top: 9pt;padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">machine learning algorithms 44 MACIS, thyroid cancer staging 215 MAG3 (mercaptoacetyl triglyceride)</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 83%;text-align: left;">gastric cancer treatment planning 111 renogram 21–22</p><p class="s138" style="padding-left: 27pt;text-indent: -16pt;line-height: 83%;text-align: left;">magnetic resonance angiography (MRA) 261–62</p><p class="s138" style="padding-left: 27pt;text-indent: -16pt;line-height: 83%;text-align: left;">magnetic resonance-based computed tomography equivalent images 35</p><p class="s138" style="padding-left: 27pt;text-indent: -16pt;line-height: 83%;text-align: left;">magnetic resonance cholangiopancreatography (MRCP) 120, 130</p><p class="s138" style="padding-left: 27pt;text-indent: -16pt;line-height: 83%;text-align: left;">magnetic resonance spectroscopy (MRS) 223, 291</p><p class="s138" style="padding-left: 27pt;text-indent: -16pt;line-height: 83%;text-align: left;">MALT <i>see </i>mucosa-associated lymphoid tissue (MALT)</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 9pt;text-align: left;">MALTomas 249</p><p class="s138" style="padding-left: 27pt;text-indent: -16pt;line-height: 83%;text-align: left;">mammography, breast cancer 47–50, 48<i>f</i>, 49<i>f</i>, 50<i>f</i></p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">mantle cell lymphoma 87<i>t </i>mAs (milliampere second) 9 mastectomy specimens 52</p><p class="s138" style="padding-left: 19pt;text-indent: -8pt;line-height: 83%;text-align: left;">maximum intensity projection (MIP) scan CT 9</p><p class="s138" style="padding-left: 11pt;text-indent: 8pt;line-height: 83%;text-align: left;">lung cancer radiotherapy planning 72 maximum standardized uptake values</p><p class="s138" style="padding-left: 27pt;text-indent: 0pt;line-height: 9pt;text-align: left;">(SUV<span class="s142">max</span>) 28</p><p class="s138" style="padding-left: 27pt;text-indent: -16pt;line-height: 83%;text-align: left;">MCNs (mucinous neoplasms of pancreas) 132–33</p><p class="s138" style="padding-left: 27pt;text-indent: -16pt;line-height: 83%;text-align: left;">MDCT <i>see </i>multi-detector computed tomography (MDCT)</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">mechanical focusing, ultrasound 13 mediastinoscopy 69–70</p><p class="s138" style="padding-left: 27pt;text-indent: -16pt;line-height: 83%;text-align: left;">medical exposure regulations <i>see </i>ionising radiation (medical exposure) regulations (IR(ME)R 2017)</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">medical physics expert (MPE) 360 medulloblastoma 238–39, 239<i>f </i>megavoltage portal imaging 365 MEN-1 (multiple endocrine neoplasia</p><p class="s138" style="padding-left: 27pt;text-indent: 0pt;line-height: 9pt;text-align: left;">type-1) 266</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 9pt;text-align: left;">meningioma 244<i>f</i>, 244–45</p><p class="s138" style="padding-left: 11pt;text-indent: 8pt;line-height: 83%;text-align: left;">orbital tumours 249 mercaptoacetyl triglyceride <i>see </i>MAG3</p><p class="s138" style="padding-left: 27pt;text-indent: 0pt;line-height: 9pt;text-align: left;">(mercaptoacetyl triglyceride)</p><p class="s138" style="padding-left: 27pt;text-indent: -16pt;line-height: 83%;text-align: left;">MESCC (metastatic epidural spinal cord compression) 323<i>f</i>, 323–24</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 9pt;text-align: left;">mesenteric lymph nodes 110</p><p class="s138" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 10pt;text-align: left;">MET <span class="s143">(11</span>C-methionine) 224</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">metabolic tumour volume (MTV) 28 125I metaiodobenzylguanidine (mIBG)</p><p class="s138" style="padding-left: 21pt;text-indent: 0pt;line-height: 9pt;text-align: left;">scintigraphy 298</p><p class="s140" style="padding-left: 21pt;text-indent: -16pt;line-height: 83%;text-align: left;">125<span class="s141">I metaiodobenzylguanidine (mIBG) scintigraphy 299</span><span class="s139">f</span></p><p class="s138" style="padding-left: 13pt;text-indent: -8pt;line-height: 83%;text-align: left;">metal implants artefacts 352<i>f</i>, 352</p><p class="s138" style="padding-left: 5pt;text-indent: 8pt;line-height: 83%;text-align: left;">MRI in radiotherapy planning 34 metastatic epidural spinal cord compression</p><p class="s138" style="text-indent: 0pt;line-height: 9pt;text-align: right;">(MESCC) 323<i>f</i>, 323–24</p><p class="s140" style="text-indent: 0pt;line-height: 9pt;text-align: right;">11<span class="s141">C-methionine (MET) 224</span></p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">methotrexate pulmonary toxicity 327–28 methyl-guanine methyl transferase</p><p class="s138" style="padding-left: 21pt;text-indent: 0pt;line-height: 9pt;text-align: left;">(MGMT) 227</p><p class="s138" style="padding-left: 21pt;text-indent: -16pt;line-height: 83%;text-align: left;">MGMT (methyl-guanine methyl transferase) 227</p><p class="s139" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;"><span class="s140">123</span><span class="s141">I-MIBG scintigraphy 271</span>f<span class="s138">, 271–72, 302, 303</span>f <span class="s138">midgut neuroendocrine neoplasms 268–69 MinNP (minimum intensity projections) 9 MIP </span>see <span class="s138">maximum intensity projection</span></p><p class="s138" style="padding-left: 21pt;text-indent: 0pt;line-height: 9pt;text-align: left;">(MIP) scan</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 9pt;text-align: left;">mixed gliomas 234–36</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 83%;text-align: left;">follow-up imaging 231<i>f</i>, 234–36, 236<i>f </i>gliomatosis cerebri 234</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">spinal cord gliomas 234–36, 235<i>f</i></p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">mixed hepatocellular cholangiocarcinoma 122 molecular imaging 2</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 83%;text-align: left;">anal cancer diagnosis/staging 162 lymphoma diagnosis 87–89</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">molecularly targeted agents (MTAs) 126 MPE (medical physics expert) 360</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">MRA (magnetic resonance angiography) 261–62 MRCP (magnetic resonance</p><p class="s138" style="padding-left: 5pt;text-indent: 16pt;line-height: 83%;text-align: left;">cholangiopancreatography) 120, 130 mucinous neoplasms of pancreas</p><p class="s138" style="padding-left: 21pt;text-indent: 0pt;line-height: 9pt;text-align: left;">(MCNs) 132–33</p><p class="s138" style="padding-left: 13pt;text-indent: -8pt;line-height: 83%;text-align: left;">mucosa-associated lymphoid tissue (MALT) lymphoma 87<i>t</i></p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">non-Hodgkin lymphoma (NHL) 84</p><p class="s138" style="padding-left: 13pt;text-indent: -8pt;line-height: 83%;text-align: left;">multi-detector computed tomography (MDCT) lung cancer radiotherapy planning 71–72, 72<i>f </i>pancreatic tumour diagnosis 130</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">pancreatic tumour staging 131</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">multi-detector helical computed tomography 8, 8<i>t </i>multi-gated acquisition scan SPECT 23–24 multi-parametric magnetic resonance</p><p class="s138" style="padding-left: 21pt;text-indent: 0pt;line-height: 9pt;text-align: left;">imaging 44, 168</p><p class="s138" style="padding-left: 21pt;text-indent: -16pt;line-height: 83%;text-align: left;">multi-parametric positron emission tomography 44</p><p class="s138" style="padding-left: 13pt;text-indent: -8pt;line-height: 83%;text-align: left;">multiplanar recobstructions (MPRs) CT image processing 9, 10<i>f </i>gastric cancer 109, 110<i>f</i></p><p class="s138" style="padding-left: 5pt;text-indent: 8pt;line-height: 83%;text-align: left;">gastric cancer T staging 109<i>f</i>, 109 multiple endocrine neoplasia type-1</p><p class="s138" style="padding-left: 21pt;text-indent: 0pt;line-height: 9pt;text-align: left;">(MEN-1) 266</p><p class="s138" style="padding-top: 8pt;padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">natural killer cell lymphoma 87<i>t </i>nephroblastoma 294</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 9pt;text-align: left;">nephroblastomatosis 294–95</p><p class="s138" style="padding-top: 7pt;padding-left: 21pt;text-indent: -16pt;line-height: 83%;text-align: left;">nerve sheath tumours, benign 247–48, 248<i>f</i></p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 9pt;text-align: left;">neuroendocrine tumours 265–69</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">lungs 269, 270<i>f</i></p><p class="s138" style="padding-left: 21pt;text-indent: -8pt;line-height: 83%;text-align: left;">midgut neuroendocrine neoplasms 268–69</p><p class="s138" style="padding-left: 21pt;text-indent: -8pt;line-height: 83%;text-align: left;">pancreas <i>see </i>pancreatic neuroendocrine tumours (PNETs)</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">neutropenic colitis (typhilitis) 319–20, 320<i>f </i>NHS breast cancer screening programme</p><p class="s138" style="padding-left: 21pt;text-indent: 0pt;line-height: 9pt;text-align: left;">(NHSBSP) 46, 60</p><p class="s138" style="padding-left: 13pt;text-indent: -8pt;line-height: 83%;text-align: left;">non-Hodgkin lymphoma (NHL) characteristics 84</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">children 302</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">definition 82</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">orbital lymphoma 249</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">therapeutic response 93–95</p><p class="s138" style="padding-left: 21pt;text-indent: -16pt;line-height: 83%;text-align: left;">non-seminomatous germ cell tumours (NSGCT) 182–83</p><p class="s138" style="padding-left: 13pt;text-indent: -8pt;line-height: 83%;text-align: justify;">non-small cell lung cancer (NSCLC) dose escalation/dose painting 42 histology 64</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: justify;">radiotherapy planning 39</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 10pt;text-align: justify;">TNM staging 67</p><p class="s138" style="padding-top: 8pt;padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">obstructing pancreatic tumours 129–30 obstructions 321</p><p class="s138" style="text-indent: 0pt;line-height: 9pt;text-align: right;">oesophageal tumours 98</p><p class="s138" style="text-indent: 0pt;line-height: 9pt;text-align: right;">clinical background 98</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: justify;">diagnosis 98</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: justify;">FDG-PET 30</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">follow-up 106</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">incidence 98</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">radiotherapy planning 41, 103–4</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">staging 98–103</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">therapeutic response 104–6</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 9pt;text-align: left;">oesophagitis, acute 75</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 9pt;text-align: left;">oesophagogastric junction (OGJ) 98, 108</p><p class="s138" style="padding-left: 13pt;text-indent: -8pt;line-height: 83%;text-align: left;">oligodendromas 232–33 anaplastic oligodendroglioma</p><p class="s138" style="padding-left: 21pt;text-indent: 0pt;line-height: 9pt;text-align: left;">(grade III) 233, 234<i>f</i></p><p class="s138" style="padding-left: 5pt;text-indent: 8pt;line-height: 83%;text-align: left;">oligodendrogliomas (grade II) 232–33, 233<i>f </i>orbital lymphoma 249</p><p class="s138" style="padding-left: 13pt;text-indent: -8pt;line-height: 83%;text-align: left;">orbital tumours 248–49 dysthyroid eye disease/thyroid</p><p class="s138" style="padding-left: 21pt;text-indent: 0pt;line-height: 9pt;text-align: left;">orbitopathy 248–49, 249<i>f</i></p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">lymphoma 249</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">meningioma 249</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">metastases 249</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">pseudo-tumour 249</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 9pt;text-align: left;">orchidectomy 183</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">osteogenic bone sarcomas 275 osteoporosis 328–29</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">avascular necrosis 329</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 83%;text-align: left;">pelvic insufficiency fractures 328–29 verbal compression fractures 328</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 9pt;text-align: left;">osteosarcoma 275</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 83%;text-align: left;">clinical features 277, 278<i>f </i>diagnosis/staging 280</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 9pt;text-align: left;">ovarian cancer 193</p><p class="s138" style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;line-height: 10pt;text-align: left;">palliative radiotherapy 135</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">pancreas, obstructive tumours 129–30 pancreatic neuroendocrine tumours</p><p class="s138" style="padding-left: 27pt;text-indent: 0pt;line-height: 9pt;text-align: left;">(PNETs) 266–68</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 83%;text-align: left;">clinical background 266 diagnosis and staging 266–67</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">therapeutic assessment/follow-up 267–68</p><p class="s138" style="padding-left: 81pt;text-indent: 0pt;line-height: 9pt;text-align: center;">pancreatic tumours 128</p><p class="s138" style="padding-left: 77pt;text-indent: 0pt;line-height: 9pt;text-align: center;">diagnosis 128–31</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">incidence 128</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 83%;text-align: left;">mucinous neoplasms 132–33 neuroendocrine tumours <i>see </i>pancreatic</p><p class="s138" style="padding-left: 19pt;text-indent: 8pt;line-height: 83%;text-align: left;">neuroendocrine tumours (PNETs) radiotherapy planning 133–35 secondary signs 129<i>t</i></p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">staging 131</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">symptoms 128</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 83%;text-align: left;">therapeutic assessment/ follow-up 135 therapeutic staging 131–32, 132<i>t</i></p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 9pt;text-align: left;">parotid gland tumours 213</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">pathological complete response (pCR) 104 patient compliance 336–37</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 9pt;text-align: left;">patient dose audit 363</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">pCCA <i>see </i>perihilar cholangiocarcinoma (pCCA) PCNSL (primary CNS lymphoma) 239–40,</p><p class="s138" style="padding-left: 27pt;text-indent: 0pt;line-height: 9pt;text-align: left;">240<i>f</i></p><p class="s138" style="padding-left: 27pt;text-indent: -16pt;line-height: 83%;text-align: left;">pelvic insufficiency fractures (PIF) 328–29, 329<i>f</i></p><p class="s138" style="padding-left: 27pt;text-indent: -16pt;line-height: 83%;text-align: left;">PERCIST (PET Response Criteria in Solid Tumours) 30, 62</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">percutaneous intravascular stenting 318 percutaneous needle biopsy 295 perfusion computed tomography 143–45 perfusion magnetic resonance imaging 75</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">perfusion scanning, pulmonary embolism 317 perihilar cholangiocarcinoma (pCCA) 118</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">diagnosis 120–21</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">peripheral nerve sheath tumours (PNSTs) 255 peripheral T cell lymphoma 87<i>t</i></p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Perlman syndrome 294</p><p class="s138" style="padding-left: 27pt;text-indent: -16pt;line-height: 83%;text-align: left;">PET Response Criteria in Solid Tumours (PERCIST) 30, 62</p><p class="s138" style="padding-left: 27pt;text-indent: -16pt;line-height: 83%;text-align: left;">phaeochromocytoma and paraganglioma (PPGLs) 269–72</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">clinical background 269–70</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">diagnosis/staging 270–71</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">prevalence 269–70</p><p class="s138" style="padding-left: 27pt;text-indent: -8pt;line-height: 83%;text-align: left;">therapeutic assessment/follow-up 271<i>f</i>, 271–72</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">photoelectric effect, radiography 6 physiological process map, SPECT 22</p><p class="s138" style="padding-left: 27pt;text-indent: -16pt;line-height: 83%;text-align: left;">PI-RADS (Prostate Imaging Reporting and Data System) 168, 169<i>t</i></p><p class="s138" style="padding-left: 27pt;text-indent: -16pt;line-height: 83%;text-align: left;">PIF (pelvic insufficiency fractures) 328–29, 329<i>f</i></p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">pilocytic astrocytomas (grade I) 231<i>f</i>, 231–32 pineal lesions 240–42</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 83%;text-align: left;">germ cell tumours 241, 242<i>f </i>pineoblastoma 240, 241</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">pineocytoma 241</p><p class="s138" style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;line-height: 10pt;text-align: left;">pineoblastoma 240, 241</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 9pt;text-align: left;">pineocytoma 241</p><p class="s138" style="padding-left: 27pt;text-indent: -16pt;line-height: 83%;text-align: left;">PIOPED (Prospective Investigation of Pulmonary Embolism Diagnosis) 315–16</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 9pt;text-align: left;">pituitary gland</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">adenoma 245–46, 246<i>f</i></p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">macroadenomas 245, 246<i>f</i></p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">microadenomas 245</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">radiotherapy planning 38</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">pleomorphic salivary gland tumours 212–13 pleural effusions 56, 327</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 9pt;text-align: left;">pleural mesothelioma 79</p><p class="s138" style="padding-left: 27pt;text-indent: -16pt;line-height: 83%;text-align: left;">PNETs <i>see </i>pancreatic neuroendocrine tumours (PNETs)</p><p class="s139" style="padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">Pneumocystis jirovecii <span class="s138">infection 324, 325</span>f <span class="s138">pneumonia</span></p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">bleomycin-induced 327–28</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">interstitial 332</p><p class="s138" style="padding-left: 11pt;text-indent: 8pt;line-height: 83%;text-align: left;">symptomatic radiation pneumonitis 74–75 pneumonitis</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 83%;text-align: left;">acute pneumonitis 77, 78<i>f </i>immune-related 331–32, 332<i>f</i></p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 9pt;text-align: left;">pneumoperitoneum 322<i>f</i>, 322</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 9pt;text-align: left;">pneumothorax, spontaneous 327</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">PNSTs (peripheral nerve sheath tumours) 255 postmenopausal bleeding 194 postmenopausal patients, pelvic insufficiency</p><p class="s138" style="padding-left: 27pt;text-indent: 0pt;line-height: 9pt;text-align: left;">fractures 328</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">pregnancy, radiation issues 361–62 primary bone sarcomas 275</p><p class="s138" style="padding-left: 27pt;text-indent: -8pt;line-height: 83%;text-align: left;">diagnosis/staging 276–84, 276<i>t</i>, 278<i>f</i>, 279<i>f</i>, 280<i>f</i>, 281<i>f</i>, 283<i>f</i>, 284<i>f</i>, 285<i>f</i></p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 83%;text-align: left;">interventional radiology 284–86, 285<i>f </i>metastases 286</p><p class="s138" style="padding-left: 11pt;text-indent: 8pt;line-height: 83%;text-align: left;">treatment response/follow-up 286–87 primary bone tumours 309</p><p class="s138" style="padding-left: 27pt;text-indent: -16pt;line-height: 83%;text-align: left;">primary CNS lymphoma (PCNSL) 239–40, 240<i>f</i></p><p class="s138" style="padding-left: 27pt;text-indent: -16pt;line-height: 83%;text-align: left;">Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED) 315–16</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 9pt;text-align: left;">prostate cancer 168–78</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">clinical background 168</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">diagnosis 168</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 83%;text-align: left;">dose escalation/dose painting 42–43 imaging radiation dose 366<i>t</i>, 368–69 radiotherapy planning 40–41, 174–75, 175<i>f</i></p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">staging 27, 168–72, 171<i>f</i>, 173<i>f</i>, 174<i>f</i></p><p class="s138" style="padding-left: 11pt;text-indent: 8pt;line-height: 83%;text-align: left;">therapeutic assessment/follow-up 175–77 prostate gland 347<i>f</i>, 347</p><p class="s138" style="padding-left: 27pt;text-indent: -16pt;line-height: 83%;text-align: left;">Prostate Imaging Reporting and Data System (PI-RADS) 168, 169<i>t</i></p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">prostate-specific membrane antigen (PSMA) 41 proton density, MRI 18<i>f</i>, 18</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">PSA (prostate-specific antigen) 172, 175–76 pseudo-tumour, orbital tumours 249 pseudomembranous colitis 319–21, 320<i>f</i></p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">PSMA (prostate-specific membrane antigen) 41 pulmonary embolism (PE) 315–16</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">clinical assessment 315–16</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 10pt;text-align: left;">D-dimer 316</p><p class="s138" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 10pt;text-align: left;">pulmonary fibrosis 74–75</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 10pt;text-align: left;">pulsed Doppler 14</p><p class="s138" style="padding-top: 7pt;text-indent: 0pt;line-height: 10pt;text-align: right;">radiation effects 356–57</p><p class="s138" style="text-indent: 0pt;line-height: 9pt;text-align: right;">absorbed dose 357–58</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">radiation exposure, minimization in children 290 radiation-induced lung injury 326–27</p><p class="s138" style="padding-left: 13pt;text-indent: -8pt;line-height: 83%;text-align: left;">radiation protection issues 356 legislation 358–63</p><p class="s139" style="padding-left: 21pt;text-indent: -8pt;line-height: 83%;text-align: left;">see also <span class="s138">ionising radiation (medical exposure) regulations (IR(ME)R 2017)</span></p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 9pt;text-align: left;">radical hysterectomy 200</p><p class="s138" style="padding-left: 21pt;text-indent: -16pt;line-height: 83%;text-align: left;">radio-labelled choline positron emission tomography 41</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">radiofrequency ablation (RFA) 122 radiomics 44</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 9pt;text-align: left;">radionuclide radiology 20–24</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">gamma camera 20–21</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">radiopharmaceuticals (radiotracers) 20</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 9pt;text-align: left;">radiopharmaceuticals (radiotracers) 20</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">radiotracers (radiopharmaceuticals) 20 RECIST <i>see </i>Response Evaluation Criteria in</p><p class="s138" style="padding-left: 5pt;text-indent: 16pt;line-height: 83%;text-align: left;">Solid Tumours (RECIST) rectal cancer 148</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">clinical background 148</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">diagnosis 149</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 83%;text-align: left;">dose escalation/dose painting 42 radiotherapy planning 40</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">staging 27, 148, 149<i>f</i>, 149–54</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">surveillance 158</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">therapeutic assessment 156–58</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">treatment planning 155–56</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">recurrent laryngeal nerve (RLN) 215–18 recurrent rectal cancer metastatic staging 154 reference images 342, 346<i>f</i></p><p class="s138" style="padding-left: 13pt;text-indent: -8pt;line-height: 83%;text-align: left;">renal cell carcinoma (RCC) 187–90 clinical background 187</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">diagnosis 188–89</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 83%;text-align: left;">radiotherapy planning 189 staging 188<i>t</i>, 189<i>f</i>, 189</p><p class="s138" style="padding-left: 5pt;text-indent: 8pt;line-height: 83%;text-align: left;">therapeutic assessment/follow-up 190 renal mass lesion classification 188–89 resectable pancreatic tumours 131 respiratory motion, lung cancer radiotherapy</p><p class="s138" style="padding-left: 21pt;text-indent: 0pt;line-height: 9pt;text-align: left;">planning 71–72</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">respiratory symptoms, lymphoma 83–84 respiratory tract infections 324, 325<i>f</i></p><p class="s138" style="padding-left: 21pt;text-indent: -16pt;line-height: 83%;text-align: left;">Response Evaluation Criteria in Solid Tumours (RECIST) 30, 62, 76–77</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">gastric cancer 112</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 83%;text-align: left;">gastrointestinal stromal tumours 143–45 hepatobiliary tumours 125, 126</p><p class="s138" style="padding-left: 5pt;text-indent: 8pt;line-height: 83%;text-align: left;">midgut neuroendocrine neoplasms 268–69 retropancreatic nodes 110</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 9pt;text-align: left;">retroperitoneal sarcomas 255</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 9pt;text-align: left;">retroperitoneum 297</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">RFA (radiofrequency ablation) 122 rhabdomyosarcoma 308<i>f</i></p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">alveolar rhabdomyosarcoma 310</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 10pt;text-align: left;">embryonal rhabdomyosarcoma 310</p><p class="s138" style="padding-top: 7pt;padding-left: 21pt;text-indent: -16pt;line-height: 83%;text-align: left;">s-CT (substitute (synthetic) computed tomography) 35</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 9pt;text-align: left;">sacrum</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">chordomas 285<i>f</i>, 286</p><p class="s138" style="padding-left: 5pt;text-indent: 8pt;line-height: 83%;text-align: left;">pelvic insufficiency fractures 328–29 salivary gland tumours 212–13 sarcoma</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 83%;text-align: left;">chondrogenic bone sarcomas 275 Ewing’s sarcoma <i>see </i>Ewing’s sarcoma primary bone <i>see </i>primary bone sarcomas retroperitoneal sarcomas 255</p><p class="s138" style="padding-left: 5pt;text-indent: 8pt;line-height: 83%;text-align: left;">soft tissue <i>see </i>soft tissue sarcomas scattering, ultrasound 12–13 scintigraphy</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">bone scintigraphy <i>see </i>bone scintigraphy</p><p class="s139" style="padding-left: 13pt;text-indent: 0pt;line-height: 83%;text-align: left;"><span class="s140">123</span><span class="s141">I-MIBG scintigraphy 271</span>f<span class="s138">, 271–72, 302, 303</span>f <span class="s138">whole body scintigraphy 261</span></p><p class="s138" style="padding-left: 21pt;text-indent: -16pt;line-height: 83%;text-align: left;">selective internal radiation therapy (SIRT) 124–25, 125<i>f</i></p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">sellar region, CNS tumours 245–47 seminoma 185</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 9pt;text-align: left;">sepsis 324</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">seroma, breast imaging 349<i>f</i>, 349 SHH (sonic hedgehog) mutations 238 silicone-laden nodes, PET/CT 52, 53<i>f</i></p><p class="s138" style="padding-left: 21pt;text-indent: -16pt;line-height: 83%;text-align: left;">single photon emission computed topography (SPECT) 21</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">CNS tumours 224</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">hepatobiliary tumour 124</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">imaging 21–24</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">multi-gated acquisition scan 23–24</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">multi-gated acquisition scan SPECT 23–24</p><p class="s139" style="padding-left: 5pt;text-indent: 8pt;line-height: 83%;text-align: left;">see also <span class="s138">isotope bone scans SIRT (selective internal radiation</span></p><p class="s138" style="padding-left: 5pt;text-indent: 16pt;line-height: 83%;text-align: left;">therapy) 124–25, 125<i>f </i>small-cell lung cancer (SCLC)</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">histology 64</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">radiotherapy 79</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">TNM staging 67</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">small lymphocytic lymphoma 87<i>t </i>soft tissue sarcomas 251</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">anatomical locations 255</p><p class="s138" style="padding-left: 21pt;text-indent: -8pt;line-height: 83%;text-align: left;">diagnosis and staging 251–61, 252<i>f</i>, 252<i>t</i>, 254<i>f</i>, 256<i>f</i>, 257<i>f</i>, 258<i>f</i>, 259<i>f</i>, 260<i>f</i>, 261<i>f</i></p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 83%;text-align: left;">fat content 255, 256<i>f </i>follow-up 262–64</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 83%;text-align: left;">local recurrence 263<i>f</i>, 263–64 lymph node metastases 255–56 metastatic disease 264 treatment response 262, 263<i>f</i></p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 9pt;text-align: left;">somatostatinomas 266</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">sonic hedgehog (SHH) mutations 238 spatial compound imaging, ultrasound 14 spatial resolution, radiography imaging 6</p><p class="s138" style="padding-left: 21pt;text-indent: -16pt;line-height: 83%;text-align: left;">SPECT <i>see </i>single photon emission computed topography (SPECT)</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 9pt;text-align: left;">spinal cord</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 83%;text-align: left;">gliomas 234–36, 235<i>f </i>lung cancer metastases 75</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">myxopapillary ependymoma (grade II) 237–38</p><p class="s138" style="padding-top: 7pt;padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">spleen, lymphoma staging 89 spontaneous pneumothorax 327 spot data acquisition, SPECT 21–22 squamous cell carcinoma (SCC)</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">anal squamous cell carcinoma 160</p><p class="s138" style="padding-left: 27pt;text-indent: -8pt;line-height: 83%;text-align: left;">head and neck <i>see </i>head and neck squamous cell carcinoma (HNSCC)</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">lung cancer 64</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 83%;text-align: left;">oesophageal cancer 98, 101 parotid gland tumours 213</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">standardized uptake value (SUV) 211 stereotactic ablative radiotherapy (SABR) 29</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">lung cancer 71, 74</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">pancreatic tumours 133–34</p><p class="s138" style="padding-left: 19pt;text-indent: -8pt;line-height: 83%;text-align: left;">stereotactic body radiation therapy (SBRT) hepatobiliary tumours 125</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">lung cancer 71, 74</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">pancreatic tumours 133–34</p><p class="s138" style="padding-left: 27pt;text-indent: -8pt;line-height: 83%;text-align: left;">renal cell carcinoma radiotherapy planning 189</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 9pt;text-align: left;">stereotactic radiosurgery (SRS) 242</p><p class="s138" style="padding-left: 27pt;text-indent: -16pt;line-height: 83%;text-align: left;">STIR (short tau inverse recovery) magnetic resonance imaging 209–10, 253–54</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">stochastic effects of radiation 356 stomach cancer <i>see </i>gastric tumours</p><p class="s138" style="padding-left: 27pt;text-indent: -16pt;line-height: 83%;text-align: left;">superior vena cava obstruction (SVCO) 318, 319<i>f</i></p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">supraclavicular fossa (SCF) 56 surgical clips 60</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">SUV (standardized uptake value) 211 SUV<span class="s142">max </span>(maximum standardized uptake</p><p class="s138" style="padding-left: 27pt;text-indent: 0pt;line-height: 7pt;text-align: left;">values) 28</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">SVCO (superior vena cava obstruction) 318, 319<i>f </i>symptomatic radiation pneumonitis 74–75</p><p class="s138" style="padding-top: 9pt;padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">T cell lymphoma, diagnosis 87<i>t </i>T stage</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 83%;text-align: left;">bladder cancer 174–75, 179<i>f</i>, 180<i>f </i>gastric tumour 109–10, 110<i>f</i></p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">lung cancer 68–69</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 83%;text-align: left;">oesophageal tumour 99–101 prostate cancer 169–71, 171<i>f</i></p><p class="s138" style="padding-left: 27pt;text-indent: -16pt;line-height: 83%;text-align: left;">TA(C)E (transarterial (chemo) embolization) 122, 123–25</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 9pt;text-align: left;">TAUS <i>see </i>transabdominal ultrasound (TAUS)</p><p class="s140" style="padding-left: 27pt;text-indent: -16pt;line-height: 83%;text-align: justify;">99m<span class="s141">technetium--phosphonate bone scan, paediatric bone tumour diagnosis/ staging 307–8</span></p><p class="s140" style="padding-left: 11pt;text-indent: 0pt;line-height: 9pt;text-align: left;">99m<span class="s141">-technetium diphosphonate bone scans 311</span></p><p class="s140" style="padding-left: 27pt;text-indent: -16pt;line-height: 83%;text-align: left;">99m<span class="s141">technetium-HMPAO (hexamethylpropylene amine oxime) 224</span></p><p class="s140" style="padding-left: 27pt;text-indent: -16pt;line-height: 83%;text-align: left;">99<span class="s141">m-technetium macroaggregated albumin (MAA) 124</span></p><p class="s140" style="padding-left: 27pt;text-indent: -16pt;line-height: 83%;text-align: left;">99m<span class="s141">-technetium methylene diphosphonate (MDP) 22, 23</span><span class="s139">f</span><span class="s138">, 281–83</span></p><p class="s140" style="padding-left: 27pt;text-indent: -16pt;line-height: 83%;text-align: left;">99<span class="s141">m-technetium, soft tissue sarcoma diagnosis/ staging 261</span></p><p class="s140" style="padding-left: 11pt;text-indent: 0pt;line-height: 9pt;text-align: left;">99m<span class="s141">Tc(technetium) 20</span></p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 9pt;text-align: left;">testicular cancer 182–85</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 10pt;text-align: left;">clinical background 182–83</p><p class="s138" style="padding-top: 5pt;padding-left: 19pt;text-indent: 0pt;line-height: 10pt;text-align: left;">diagnosis 183<i>f</i>, 183</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">radiotherapy planning 185</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">staging 183, 184<i>f</i></p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">therapeutic assessment/follow-up 185</p><p class="s140" style="padding-left: 11pt;text-indent: 0pt;line-height: 9pt;text-align: left;">201<span class="s141">thallium chloride 224</span></p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 9pt;text-align: left;">thymomas 79</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 9pt;text-align: left;">thyroid cancer 213–14</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 83%;text-align: left;">anaplastic thyroid cancer 217<i>t </i>diagnosis 214</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">recurrence 219</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">staging 214–19</p><p class="s138" style="padding-left: 27pt;text-indent: -16pt;line-height: 83%;text-align: left;">thyroid orbitopathy/dysthyroid ere disease 248–49, 249<i>f</i></p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">thyroid-stimulating hormone (TSH) 219 tissue harmonic imaging, ultrasound 13–14 TNM staging</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">anal cancer 162</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 9pt;text-align: left;">breast cancer 53</p><p class="s138" style="padding-left: 19pt;text-indent: 0pt;line-height: 83%;text-align: left;">head and neck cancer 216<i>t </i>lung cancer 67, 67<i>t</i>, 69<i>t </i>oesophageal cancer 98, 100<i>t </i>pancreatic tumours 131 prostate cancers 168–69, 170<i>t </i>rectal cancers 150, 151<i>t </i>testicular cancers 183</p><p class="s138" style="padding-left: 11pt;text-indent: 8pt;line-height: 83%;text-align: left;">thyroid cancers 215 transabdominal ultrasound (TAUS)</p><p class="s138" style="padding-left: 27pt;text-indent: -8pt;line-height: 83%;text-align: left;">gastrointestinal stromal tumour diagnosis 143</p><p class="s138" style="padding-left: 11pt;text-indent: 8pt;line-height: 83%;text-align: left;">pancreatic tumour diagnosis 128 transarterial (chemo)embolization</p><p class="s138" style="padding-left: 27pt;text-indent: 0pt;line-height: 9pt;text-align: left;">(TA(C)E) 122, 123–25</p><p class="s138" style="text-indent: 0pt;line-height: 9pt;text-align: right;">transducers 13</p><p class="s138" style="text-indent: 0pt;line-height: 9pt;text-align: right;">diameter 13</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">transoesophageal echocardiography 317, 324 transoesophageal endoscopic ultrasound 66<i>f</i>,</p><p class="s138" style="padding-left: 27pt;text-indent: 0pt;line-height: 9pt;text-align: left;">66, 100–1, 189</p><p class="s138" style="padding-left: 19pt;text-indent: -8pt;line-height: 83%;text-align: left;">transrectal ultrasonography (TRUS) 153<i>f</i>, 153 prostate cancer radiotherapy planning 175,</p><p class="s138" style="padding-left: 27pt;text-indent: 0pt;line-height: 9pt;text-align: left;">176<i>f</i>, 177<i>f</i></p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">transthoracic echocardiography 317 transurethral resection of bladder tumour</p><p class="s138" style="padding-left: 27pt;text-indent: 0pt;line-height: 9pt;text-align: left;">(TURBT) 180</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">transurethral resection (TUR) 178 transvaginal ultrasound (TVUS) 194</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">TRG (tumour regression grade) 156–57, 157<i>t </i>triple negative breast cancer (TNBC) 54</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">tube current, radiography imaging 5 tube kilovoltage, radiography imaging 5</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">tube target material, radiography imaging 5 tumour regression grade (TRG) 156–57, 157<i>t </i>TURBT (transurethral resection of bladder</p><p class="s138" style="padding-left: 27pt;text-indent: 0pt;line-height: 9pt;text-align: left;">tumour) 180</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 9pt;text-align: left;">TVUS (transvaginal ultrasound) 194</p><p class="s138" style="padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">two-colour wash, match techniques 342, 346<i>f </i>typhilitis (neutropenic colitis) 319–20, 320<i>f</i></p><p class="s138" style="padding-top: 9pt;padding-left: 11pt;text-indent: 0pt;line-height: 83%;text-align: left;">ultra-small particles of iron oxide (USPIO) 172 upper urinary tract urothelial tumours 182 urethral cancers 190, 191<i>f</i></p><p class="s138" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 10pt;text-align: left;">urinary 5-HIAA 268</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 9pt;text-align: left;">urological cancers 168</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">penile cancer 186–87</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 83%;text-align: left;">upper urinary tract urothelial tumours 182 urethral cancers 190</p><p class="s139" style="padding-left: 21pt;text-indent: -8pt;line-height: 83%;text-align: left;">see also <span class="s138">bladder cancer; prostate cancer; renal cell carcinoma (RCC); testicular cancer</span></p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">urothelial transitional cell carcinomas 182 USPIO (ultra-small particles of iron oxide) 172 uterine cancer 193–97</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">clinical background 193</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">diagnosis/staging 194–96, 195<i>f</i></p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">leiomyosarcomas 255</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">radiotherapy planning 196–97</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 9pt;text-align: left;">sarcomas 195–96</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 10pt;text-align: left;">therapeutic assessment/follow-up 197</p><p class="s138" style="padding-top: 8pt;padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">vacuum-assisted biopsy 48–49, 49<i>t </i>vaginal cancer 202–4</p><p class="s138" style="padding-left: 21pt;text-indent: -16pt;line-height: 83%;text-align: left;">vascular imaging, soft tissue sarcoma 261–62, 262<i>f</i></p><p class="s138" style="padding-left: 13pt;text-indent: -8pt;line-height: 83%;text-align: left;">venous thromboembolism (VTE) 315–18, 316<i>t see also </i>pulmonary embolism (PE)</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">ventilation scanning, pulmonary embolism 317 verbal compression fractures 328</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">VIN (vulval intra-epithelial neoplasia) 204 VIPomas 266</p><p class="s138" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">VIRADS imaging reporting 179<i>t </i>virtual gross tumour volume 300–2</p><p class="s138" style="padding-left: 21pt;text-indent: -16pt;line-height: 83%;text-align: left;">volume computed tomography dose index (CTDI<span class="s142">vol</span>) 10</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 7pt;text-align: left;">volumetric cone-beam computed</p><p class="s138" style="padding-left: 21pt;text-indent: 0pt;line-height: 9pt;text-align: left;">tomography 339</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">volumetric magnetic resonance imaging 226 volumetric match techniques 342–46, 343–45<i>t</i>, 346<i>f </i>volumetric modulated arc therapy (VMAT) 2 voluntary movements, unwanted 336–37</p><p class="s138" style="padding-left: 13pt;text-indent: -8pt;line-height: 83%;text-align: left;">VTE (venous thromboembolism) 315–18, 316<i>t see also </i>pulmonary embolism (PE)</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 9pt;text-align: left;">vulval cancer 204–6</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 10pt;text-align: left;">vulval intra-epithelial neoplasia (VIN) 204</p><p class="s138" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;line-height: 10pt;text-align: left;">WAGR syndrome 294</p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 78%;text-align: left;">water diffusion, MRI 18<i>f</i>, 19 weighting factor (w<span class="s142">T</span>) 357, 358<i>t </i>Wells score 316<i>t</i></p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">whole body scintigraphy 261 Wilms’ tumour</p><p class="s138" style="padding-left: 13pt;text-indent: 0pt;line-height: 83%;text-align: left;">children 294 staging 296<i>t</i></p><p class="s138" style="padding-left: 5pt;text-indent: 0pt;line-height: 83%;text-align: left;">WNT mutations, medulloblastoma 238 w<span class="s142">T </span>(weighting factor) 357, 358<i>t</i></p><p class="nav">&nbsp;&nbsp;</p><p class="nav">&nbsp;</p><p class="nav"><a href="part30.htm">&lt; Назад</a><span> | </span><a href="../index.html">Содержимое</a></p><p class="nav">&nbsp;&nbsp;</p></body></html>
